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ABSTRACT
Introduction: Imatinib mesylate (IM), a
selective inhibitor of the BCR-ABL tyrosine
kinase, is a well-established first-line treatment
for chronic myeloid leukemia (CML). IM is
metabolized mainly by cytochrome P450
(CYP) in the liver, specifically the CYP3A4 and
CYP3A5 enzymes. Polymorphisms in these
genes can alter the enzyme activity of IM and
may affect its response. In this study, the impact
of two single-nucleotide polymorphisms (SNPs),
CYP3A5*3 (6986A[G) and CYP3A4*18
(878T[C), on IM treatment response in CML
patients (n = 270; 139 IM resistant and 131 IM
good responders) was investigated.
Methods: Genotyping of CYP3A4*18 and
CYP3A5*3 was performed using the
polymerase chain reaction restriction fragment
length polymorphism (PCR-RFLP) technique.
The association between allelic variants and
treatment response was assessed by means of
odds ratio (OR) with 95% confidence intervals
calculated by logistic regression.
Results: Our results indicated that CML
patients carrying the heterozygous (AG) and
homozygous variant (GG) genotype of
CYP3A5*3 were associated with a significantly
lower risk of acquiring resistance with OR 0.171;
95% CI: 0.090–0.324, p\0.001 and OR 0.257;
95% CI: 0.126–0.525, p\0.001, respectively.
Although CML patients carrying the
heterozygous (TC) genotype of CYP3A4*18
showed a lower risk of acquiring resistance
toward IM (OR 0.648; 95% CI: 0.277–1.515),
the association was not statistically significant
(p = 0.316). No homozygous variant (CC)
genotype of CYP3A4*18 was detected among
the CML patients.
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Conclusion: It is concluded that polymorphism
of CYP3A5*3 is associated with IM treatment
response in Malaysian CML patients with
carriers of CYP3A5*1/*3 and CYP3A5*3/*3
genotypes posing lower risk for development
of resistance to IM.
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INTRODUCTION
Currently, imatinib mesylate (IM) is the
frontline therapy for newly diagnosed chronic
myeloid leukemia (CML) patients worldwide.
IM is a synthetic tyrosine kinase inhibitor
specifically designed to inhibit the breakpoint
cluster region (BCR)-Abelson (ABL) fusion
protein resulting from Philadelphia
chromosome translocation t(9; 22)(q34, q11)
[1]. Although IM is the gold standard drug for
CML treatment, development of resistance to
IM is a major clinical problem. The
development of resistance to IM is a
multifactorial phenomenon in patients with
CML. Resistance may be mediated by a range
of different mechanisms in which
pharmacokinetic variability due to genetic
polymorphisms in IM transport and
metabolizing genes may be potential factors.
Previously, the contribution of genetic
variations in transporter genes ABCB1 and
ABCG2 in mediating resistance/good response
to IM among Malaysian CML patients was
reported by our group [2]. Drug-metabolizing
enzymes (DME) are involved in deactivating
xenobiotics as well as biotransformation of
drugs, and polymorphisms in DME coding
genes have been reported to alter the activity
of the enzymes for some substrates [3].
Therefore, genetic variation in drug
metabolism can lead to therapeutic failures,
adverse drug effects or even fatal drug
intoxications [4].
Xenobiotic metabolism is mainly conducted
by three main cytochrome P450 (CYP) gene
families: CYP1, CYP2 and CYP3, with the most
highly expressed subfamily being the CYP3A.
Genetic variation in CYP3A activity may
influence the rate of metabolism and
elimination of CYP3A substrates including IM.
The metabolism of IM is mainly mediated by
CYP3A4 and CYP3A5 [5]. It is suggested that
CYP3A4 and CYP3A5 are important genetic
contributors to inter-individual differences in
CYP3A-dependent drug metabolism. A
polymorphism of CYP3A4*18, located at exon
10, had been reported as the common allelic
variation of CYP3A4. This polymorphism
involves nucleotide change from tyrosine
(T) to cytosine (C) transition at position 878
and results in an amino acid change from
leucine to proline at codon 293 (Leu293Pro)
[6, 7]. CYP3A4*18 had been reported to be
associated with high turnover of testosterone
and chlorpyrifos when compared to the wild
type [8]. CYP3A5*3 is another common allelic
variation in CYP3A5. Polymorphism in
CYP3A5*3 plays a crucial role in the
pharmacokinetics of these CYP3A substrates. It
is reasonable to assume that polymorphisms in
the CYP3A5 gene could lead to interindividual
variability, which has been observed in the
pharmacokinetic changes seen with CYP3A
substrates [9]. This study was designed to
investigate the frequency of single-nucleotide
polymorphisms (SNPs) CYP3A5*3 (6986A[G)
and CYP3A4*18 (878T[C) in Malaysian CML
patients undergoing IM therapy and to
determine their impact on IM’s treatment
response in these patients. To our knowledge,
this is the first study to report on the allelic and
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genotypic frequencies as well as the association
of CYP3A4*18 and CYP3A5*3 with IM response
among CML patients in the Malaysian
population.
METHODS
Subjects and DNA Extraction
The study was approved by the Research and
Ethics Committee of Universiti Sains Malaysia
and the Ministry of Health, Malaysia (ethics no.
USMKK/PPP/JEPeM [244.3.(4)] and KKM/
NHSEC/08/0804/P12-687), which complies
with the Declaration of Helsinki of 1964, as
revised in 2013. Informed consent was obtained
from all patients for being included in the
study. Subjects were recruited from various
hospitals in Malaysia including Hospital
Universiti Sains Malaysia (HUSM), Hospital
Raja Perempuan Zainab II (HRPZ), Hospital
Pulau Pinang, Hospital Raja Permaisuri
Bainun, Universiti Kebangsaan Malaysia
Medical Center (PPUKM), Sime Darby Medical
Centre and Hospital Umum Sarawak (HUS). In
this study, 270 CML patients (139 IM resistant
and 131 IM good responders) were involved
who were all BCR-ABL non-mutated. The
patients selected were Philadelphia
chromosome-positive CML patients in chronic,
accelerated or blast phase, treated for at least
12 months, with IM (400 and 600 mg,
respectively) on frontline treatment. The
patients’ characteristics are shown in Table 1.
Evaluation of imatinib response: By referring
to European LeukemiaNet recommendations
for the management of chronic myeloid
leukemia 2013 [10], hematologic, cytogenetic
and molecular criteria were accessed. Based on
this, patients were grouped into IM good
responders and IM-resistant CML patients.
Hematologic response was considered as
complete when the platelet count was
\450 9 109/l; white blood cell count
\10 9 109/L; differential without immature
granulocytes and with \5% basophils and
nonpalpable spleen. The cytogenetic response
was defined as complete (0% Ph? metaphases),
partial (1–35% Ph? metaphases), minor
(36–65% Ph? metaphases), minimal (66–95%
Ph? metaphases) and none ([95–100% Ph?
metaphases) [11]. Molecular response was best
assessed according to the International Scale
(IS) as the ratio of BCR-ABL1% on a log scale,
where 10%, 1%, 0.1%, 0.01%, 0.0032% and
0.001% correspond to a decrease of 1, 2, 3, 4, 4.5
and 5 logs, respectively, below the standard
baseline that was used in the IRIS study. A
BCR-ABL1 expression of B0.1% corresponds to
major molecular response (MMR) [10]. CML
patients who achieved the above-mentioned
response criteria were categorized as IM good
responders and those who did not achieve the
above response criteria within the specified time
frame were categorized under the IM
non-responders/resistant group.
Peripheral blood (3 ml) was collected after
obtaining written informed consents from the
subjects. Genomic DNA was extracted using a
DNA extraction kit, QIAGEN QIAamp DNA
Blood Mini kit (QIAGEN, Hilden, Germany),
according to the manufacturer’s instructions.
Genotyping was conducted at Human Genome
Centre, Universiti Sains Malaysia.
Genotyping of CYP3A4*18
Polymorphisms
Genotyping of CYP3A4*18 was performed by
using the polymerase chain reaction restriction
fragment length polymorphism (PCR–RFLP)
technique. Amplification of CYP3A4*18 was
performed by using forward
(CACATCAGAATGAAACCACC) and reverse
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(AGAGCCTTCCTACATAGAGTCA) primers.
PCR reactions were conducted in a 25-ll
volume 19 PCR buffer, 2.0 lM magnesium
chloride (MgCl2), 0.5 lM dNTPs, 0.4 lM of
each primer and 1.0 U AmpliTaq Gold
Polymerase. Denaturation was at 95 C for
2 min, followed by 35 cycles at 95 C for 30 s,
55 C for 30 s, 72 C for 30 s and a final
extension step at 72 C for 5 min. The 450-bp
PCR products were electrophoresed on a 2%
agarose gel at 100 V for 30 min.
Following PCR amplification, 4 ll of 450-bp
PCR products were digested with 1.0 unit of a
restriction enzyme (Msp1) for 1 h at 37 C. The
digested PCR products were analyzed by
electrophoresis on a 2% agarose gel at 90 V for
50 min. The homozygous wild-type allele (TT)
was identified by the presence of an undigested
band (450 bp), while the heterozygous allele
(TC) was confirmed by the presence of three
fragments at 450, 282 and 168 bp. The
homozygous variant allele (CC) was identified
by the presence of two fragments at 282 and
168 bp.
Genotyping of CYP3A5*3 Polymorphisms
Genotyping of CYP3A5*3 was performed by
using a PCR–RFLP. The 293-bp DNA fragment
that contains the CYP3A5*3 allele was amplified
with the primer pair 50-GGTCCAAACAGG
GAAGAAATA-30 (forward) and 50-CATGACTTA
GTAGACAGATGAC-30 (reverse). The PCR
reactions were conducted in a 25-ll volume of
19 PCR buffer, 2.0 lM MgCl2, 0.5 lM dNTPs,
0.4 lM of each primer and 1.0 U AmpliTaq Gold
Polymerase with a denaturation step of 95 C
for 2 min, followed by 35 cycles at 95 C for
30 s, 55 C for 30 s, 72 C for 30 s and a final
extension step at 72 C for 5 min. The 293-bp
PCR products were run on a 2% agarose gel
electrophoresis at 100 V for 30 min.
Following PCR amplification, 4 ll of PCR
products was digested by restriction enzyme
Table 1 Patients’ characteristics
IM resistant





Female 78 (56.12) 51 (38.93) 0.005
Male 61 (43.88) 80 (61.07)
Age (years)
\50 88 (63.31) 96 (73.28) 0.079
C50 51 (36.69) 35 (26.72)
Mean (mean ± SD) 43.04 ± 14.63 41.99 ± 13.33
CML stages in response to IM
Chronic phase 94 (67.63) 126 (96.18) <0.001
Accelerated phase 31 (22.30) 5 (3.82)
Blast phase 14 (10.07) –
Bold values indicate statistical signiﬁcance, which is p\0.05
CML Chronic myeloid leukemia, IM imatinib mesylate
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Ssp1 for 15 min at 37 C. The digested PCR
products were analyzed by electrophoresis on a
3% agarose gel. The homozygous wild-type
allele (AA) was identified by the presence of
148, 125 and 20 bp, whereas the homozygous
variant allele (GG) was confirmed by the
presence of fragments of 168- and 125-bp size.
The heterozygous variant allele (AG) was
identified by the presence of 168-, 148-, 125-
and 20-bp fragments.
Direct Sequencing
Following genotyping, a few samples from each
different genotype were randomly selected for
sequencing to confirm the expected sequences of
each genotype. The PCR product was purified by
using a QIAquick PCR purification kit (QIAGEN)
before sending it to First BASE Laboratories
(Kuala Lumpur, Malaysia) for sequencing.
Statistical Analysis
The frequencies of polymorphic genotypes
among IM-resistant and good-response CML
patients were compared by using the
chi-square test (v2). The odds ratios (ORs) and
95% confidence intervals (CIs) were calculated
using a binary logistic regression to investigate
the risk association of genotypes with IM
response. All statistical tests were two sided,
and statistical significance was determined as
p\0.05. SPSS v.20.0 (SPSS Inc., Chicago, IL,
USA) was utilized. Pair-wise linkage
disequilibrium (LD) indices (r2) were
determined using Haploview v.4.2 [12].
RESULTS
Two hundred seventy (270) CML patients (139
IM resistant and 131 good responders) were
successfully recruited. Table 1 shows the
patients’ characteristics. In the present study,
the gender, age andCML stages did not show any
influence on IM response (data not shown). In
the PCR-RFLP analyses, the restriction enzymes
were successfully cut at the correct regions for
CYP3A4*18 and CYP3A5*3 (Fig. 1), which was
confirmed by the sequencing result (Fig. 2). Our
study observed the allelic frequency of
CYP3A4*18 and CYP3A5*3 in Malaysian CML
patients as 4.44% and 47.41%, respectively.
Among the CML patients, the allelic frequency
of CYP3A4*18 was lower (3.60%) among the
IM-resistant group compared to good responders
(5.34%), although this difference was not
Fig. 1 Gel electrophoresis after RFLP analysis for
a CYP3A4*18 (following digestion with Msp1) and
b CYP3A5*3 (following digestion with Ssp1). a Lane 1
contained a 100-bp ladder. Lanes 2 and 4 indicated a
homozygous wild-type individual. Lane 3 showed a
heterozygous individual. b Lane 1 contained a 100-bp
ladder. Lanes 2, 3 and 6 showed homozygous variants
(GG). Lane 4 indicated a homozygous wild type (AA).
Lanes 5 and 7 showed a heterozygous individual. Lane 8
contained a 50-bp ladder
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significant. On the other hand, the allelic
frequency of CYP3A5*3 polymorphisms was
significantly (p\0.001) lower (38.85%) among
the IM-resistant group compared to the good
responders (56.49%).
The frequencies of the CYP3A4*18 and
CYP3A5*3 genotypes in IM resistant and
responders are shown in Table 2. For the
CYP3A4*18 polymorphism, only homozygous
wild-type (TT) and heterozygous (TC) genotypes
were observed among both IM-resistant and
good-response CML patients. However, the
frequency of CYP3A4*18 homozygous wild type
(TT) tended to be higher (92.81%) among the
IM-resistant group although this difference was
not statistically significant. No homozygous
variant (CC) genotype was detected among
both IM-resistant and good responders. As for
the CYP3A5*3 polymorphism, the genotypic
frequencies of the homozygous wild type (AA)
were significantly (p\0.001) higher among the
IM-resistant group (44.60% in IM resistant vs.
13.74% in IM good responders), but the
frequency of heterozygous genotype (AG) was
significantly (p\0.001) higher in the IM
good-responder group (59.54% in IM good
responders vs. 33.09% in the IM-resistant group).
To establish the risk association of
CYP3A4*18 and CYP3A5*3 polymorphisms
with IM response, a binary logistic regression
was performed (Table 3). For CYP3A4*18, there
was no significant association between the
polymorphism and the risk of acquiring
resistance toward IM. However, for CYP3A5*3
polymorphisms, both heterozygous (AG) and
homozygous variants (GG) posed significantly
(p\0.001) lower risk for acquiring resistance
toward IM. We determined that these two SNPs,
rs28371759 (CYP3A4*18) and rs776746
(CYP3A5*3), are in low linkage disequilibrium
(r2 = 0) probably as a result of recombination
occuring between the two markers (Fig. 3).
Fig. 2 Direct DNA sequencing results showing part of the
electropherogram for a CYP3A4*18 and b CYP3A5*3.
a Top panel: i a homozygous wild-type individual; ii a
heterozygous individual. b Bottom panel: i homozygous
wild-type, ii heterozygous and iii homozygous variants
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DISCUSSION
To the best of our knowledge, this is the first study
reporting the impact of polymorphism of
CYP3A4*18 and CYP3A5*3 in IM treatment
response in Malaysian CML patients. For
CYP3A4*18, no homozygous variant (*18/*18)
was detected among both IM resistant and good
responders. This is similar to the findings among
the Malaysian population reported by Ruzilawati
et al. [13] who did not detect any homozygous
variant, indicating that this genotype, which
contributes to slower metabolism of most
xenobiotics, is rather rare in theAsianpopulation.
CYP3A4*18 was detected at a frequency of
1.7% in a healthy Koreanpopulation [14], 2% in a
healthyChinese population [8], 1.3% in ahealthy
Japanese population [15] and 2.07% among
Malaysian diabetics [13]. The allelic frequencies
of CYP3A4*18 among CML patients in Malaysia
was almost double (4.44%) that reported among
Malaysian diabetics indicating that the
polymorphism may play a role in contributing
to the disease. However, in another study among
the Indian population to associate CYP3A4*18
variant alleles with IM levels, although high
inter-patient variability of IM levels were seen,
noCYP3A4*18 variants were detected to establish
any significant correlation [16].
For CYP3A5, the mutant allele CYP3A5*3 has
been reported to contribute to the variable
expression in the human liver. This mutation
Table 2 Genotype and allele frequencies of CYP3A4*18 and CYP3A5*3 polymorphisms in CML patients
SNP Rs number Frequency (%) p value
IM resistance







Homozygous wild type (*1/*1) 129 (92.81) 117 (89.13) 0.313
Heterozygous (*1/*18) 10 (7.19) 14 (10.69)
Homozygous variant (*18/*18) – – –
Allele
*1 268 (96.40) 248 (94.66) 0.325





Homozygous wild type (*1/*1) 62 (44.60) 18 (13.74) <0.001
Heterozygous (*1/*3) 46 (33.10) 78 (59.54) <0.001
Homozygous variant (*3/*3) 31 (22.30) 35 (26.72) 0.399
Allele
*1 170 (61.15) 114 (43.51) <0.001
*3 108 (38.85) 148 (56.49)
Bold values indicate statistical signiﬁcance, which is p\0.05
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in intron 3, which creates a cryptic splice site,
has been reported to cause a premature stop
codon, thus resulting in the absence of the
CYP3A5 protein [17]. In CYP3A5*3, a guanine
(G) replaces an adenine (A) at position 6986.
The CYP3A5*1 allele appears to be the main
allele associated with CYP3A5 expression and
activity. Individuals with at least one CYP3A5*1
polymorphic allele tend to express higher
amounts of CYP3A5. In the current study,
CML patients who are carriers of the
heterozygous (*1/*3) and homozygous variant
(*3/*3) genotype of CYP3A5*3 were associated
with a significantly lower risk of acquiring
resistance against IM, indicating that this
variant allele has a protective effect against the
development of IM resistance.
In the study conducted by Kim et al. [18] in a
Canadian population, the CYP3A5*1/*1
genotype had an adverse impact on
achievement of a major cytogenetic response
and complete cytogenetic response. Our
findings, which indicate that CML patients
who are carriers of CYP3A5*1/*1 genotype
tend to have a higher risk of developing
resistance to IM, are in agreement with those
of Kim et al. [18]. On the contrary, a study by
Green et al. [19] on 14 Caucasian CML patients
on IM therapy demonstrated that CML patients
with high CYP3A activity tend to respond better
to IM therapy than patients with low activity,
indicating that the response may be variable
from population to population based on the
genetic background of the patients.
CYP3A5*1/*1 genotype was reported to be
associated with IM efficacy and *3/*3 genotype
with inferior outcome among Egyptian CML
patients [20] and also among Indian CML
patients [21]. However, Takahashi et al. [22]
on Japanese patients and Angelini et al. [23] on
Caucasian patients reported no significant
association of the CYP3A5*3 polymorphism
with IM response. Our findings showed that
there is a significant association of CYP3A5*3
polymorphism with IM response but with lower
risk for development of resistance. Moreover,
we also found that the CYP3A5*1 genotype was
higher in the IM-resistant group compared with
the IM good-response group. Hence, it is
reasonable to suggest that carriers of
CYP3A5*3 tend to have a protective effect
against acquiring resistance toward IM therapy.
CYP3A5 contributes substantially to the total
metabolic clearance of many CYP3A substrates.
Since individuals with at least one CYP3A5*1
allele polymorphism express high amounts of
CYP3A5, it is reasonable to predict that
individuals with the highest clearance and
lowest oral bioavailability of CYP3A substrates
will be heterozygous or homozygous for
CYP3A5*1. Hence, carriers of heterozygous
and homozygous CYP3A5*1 genotypes may be
more likely to encounter a lack of efficacy from
a standard dose of active parent drug. Likewise,
the homozygous CYP3A5*3 genotype can lead
to a decrease in enzyme activity resulting in
lowest clearance and high bioavailability of the
Fig. 3 LD blocks of rs28371759 (CYP3A4*18) and
rs776746 (CYP3A5*3). The plot shows the r2 value as
pair-wise measure of LD
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drug. Such CML patients are expected to have a
better response to IM. As evidenced from our
study, CML patients who are carriers of the
CYP3A5*1 genotype tend to acquire resistance
toward IM treatment, and those with the
CYP3A5*3 genotype respond better to IM
treatment.
The present study has some limitations in
terms of sample size. Further studies are
required to acquire a larger patient cohort for
long-term IM response monitoring. It would
also be worthwhile to estimate the intracellular
and plasma levels of both IM and its active
metabolites and to correlate their
concentrations with the genotype pattern of
CYP3A4 and CYP3A5.
CONCLUSION
Polymorphisms of CYP3A4*18 are rather
common among Malaysian CML patients,
although they are not significantly associated
with response to IM therapy. On the other
hand, polymorphism of CYP3A5*3 is associated
with IM treatment response in Malaysian CML
patients with individuals having the CYP3A5*1/
*3 and CYP3A5*3/*3 genotypes posing lower
risks of being resistant to IM treatment.
Therefore, pretreatment genotyping of this
SNP may be important in predicting IM
response in CML patients.
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